转移性非小细胞肺癌的个体化化疗
作者
JiaWei1,TeresaMoran2,ZhengyunZou3,XiaopingQian3,LifengWang3,CarlosCamps4,WenjingHu3,ImaneChaib2,BelénSanchez2,LixiaXu3,NikiKarachaliou5,MaríaSanchez-Ronco6,BaoruiLiu3,RafaelRosell2
1ComprehensiveCancerCentreofDrumTowerHospital,MedicalSchoolofNanjingUniversity,Nanjing,China.
2CatalanInstituteofOncology,HospitalGermansTriasiPujol,CtraCanyets/n,Badalona,Spain
3ComprehensiveCancerCentreofDrumTowerHospital,MedicalSchoolofNanjingUniversity,Nanjing,China
4HospitalGeneralUniversitariodeValencia,AvTresCruces,s/n,Valencia,Spain
5BreakthroughCancerResearchUnit,PangaeaBiotechS.L,QuironDexeusUniversityHospital,SabinoArana5-19,Barcelona
6UniversidadAlcaládeHenares,Pza.SanDiegos/n,AlcaládeHenares,Madrid,Spain
译者
祝清清
摘要
转移性非小细胞肺癌(non-smallcelllungcancer，NSCLC)仍是一种致命性的疾病，近期对NSCLC亚型（主要是肺腺癌）基因的描述促进了NSCLC的靶向治疗的发展，改善了其无进展生存期，尽管如此，最终患者都将面临复发、死亡。本综述中我们
